Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01286688 | Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fasting Conditions | PHASE1 | COMPLETED | 36 | — | — | Jan 1, 2002 | Mar 1, 2002 | Jan 11, 2012 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| Terbinafine Hydrochloride | EXPERIMENTAL | Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited |
| Lamisil® 250 mg Tablets | ACTIVE_COMPARATOR | Lamisil® 250 mg Tablets of Novartis |
| Name | Type | Description |
|---|---|---|
| Terbinafine Hydrochloride Tablets, 250 mg | DRUG | Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited. |
Inclusion Criteria: * Subjects enrolled in this study will be members of the community at large. The recruitment advertisements may be done using different media (e.g. radio, newspaper, Anapharm Web site, Anapharm volunteers' data base). ---Subjects must meet all of the following criteria in order ...